Ganetespib
HSP90 inhibitor / Ganetespib is an inhibitor of heat shock protein 90 (IC50 = 19 nM, canine C2 malignant mast cells; 4 nM, canine BR malignant mast cells) binding to the N-terminal ATP site.1 It displayed potent cytotoxicity against a panel of 57 transformed cell lines of both hematologic and solid tumors with IC50’s between 14 and 280 nM.2 Ganetespib enhanced T-cell-mediated killing of human melanoma cells and potentiated responses to anti-CTLA4 and anti-PD1 therapy via upregulation of interferon response genes.3 In multiple clinical trials for various cancers.
Biochemicals & reagents
888216-25-9
STA-9090
1) Lin et al. (2008), The novel HSP90 inhibitor STA-9090 exhibits activity against Kit-dependent and -independent malignant mast cell tumors; Exp. Hematol. 36 1266 2) Ying et al. (2012), Ganetespib, a Unique Triazoline-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy; Mol. Cancer Ther. 11 475 3) Mbofung et al. (2017), HSP90 inhibition enhances cancer immunotherapy by upregulating interferon response genes; Nat. Commun. 8 451
-20°C
TARGET: HSP (Heat shock protein) -- PATHWAY: Apoptosis inducer; Cell cycle; PI3K; ERK; Autophagy -- RESEARCH AREA: Cell death; Ubiquitin/Proteasome; Cell death; Cellular stress -- DISEASE AREA: Cancer